Skip to main content
. 2020 May 8;12(5):1189. doi: 10.3390/cancers12051189

Figure 6.

Figure 6

In vivo survival improvement of dual drug-loaded liposomes in an orthotopic pancreatic tumor model. After 10 days of cell implantation, mice were imaged by using IVIS and randomized into five groups (n = 5 in each group). Then, mice were treated with indicated groups 2×/week for 3 weeks. After the end of the treatment, mice were observed, and IACUC endpoints in the AsPC-1 tumor model for survival analysis were noted. (A) Represents the experimental plan of survival study and (B) represents median survival study graph developed using GraphPad software. (C) Improved survival days with indicated treatment groups along with statistical significance with respect to the vehicle or G-L Kaplan–Meier survival plots for both EGFR (D) and MET (E) were obtained from the analysis of the Kaplan–Meier-plotter [Pan-cancer RNA-seq] database. *** denotes p < 0.001 compared to control. (Abbreviations: G-L represents liposomal gemcitabine; GP-L represents liposome loaded with both gemcitabine and paclitaxel; GE-L represents liposome loaded with both gemcitabine and erlotinib, GX-L represents liposome loaded with both gemcitabine and XL-184).